Applied DNA Signs Master Services Agreement with Schreiner Group to Deliver SigNature® DNA Labels to Protect Pharmaceutical ...
August 07 2019 - 8:30AM
Business Wire
Applied DNA
products and services offer forensic, high-value differentiation
for Schreiner MediPharm’s customers to secure supply
chains
Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”, the
“Company”), a leader in PCR-based DNA manufacturing for product
authenticity and traceability solutions, announced today the
signing of a Master Services Agreement with Germany-based Schreiner
Group, an award-winning 68-year-old company specializing in
innovative, functional labels and integrated security solutions
across many industries, including the Pharmaceutical Industry
through its Schreiner MediPharm business unit.
Applied DNA will supply its SigNature® DNA forensic molecular
tag with Beacon® screening feature for Schreiner MediPharm’s
high-end security label portfolio within the Pharmaceutical
Industry for product and brand protection of its customers’ supply
chains. Schreiner MediPharm will also provide authentication
services to its customers using the Applied DNA SigNify® portable
DNA readers now in use at the Schreiner ProSecure competence
center, providing security technologies and services to Schreiner
MediPharm as well as Schreiner Group’s other business units.
In a joint development, SigNature DNA and Beacon were integrated
in Schreiner MediPharm’s security label concepts and processes.
These were validated over the last 18 months during which time the
labels have undergone exhaustive environmental and reliability
testing by both partners.
Dr. James Hayward, President and CEO of Applied DNA, said,
“Schreiner MediPharm is an industry leader who brings top notch
science and engineering to its pharmaceutical label portfolio with
a spirit of innovation. Given the reported and continued high
incidence rate of counterfeits within the pharmaceutical supply
chain, we firmly believe the forensic SigNature DNA-protected
labels will be of significant value in ensuring authentic medicines
reach patients.”
Dr. Nadine Lampka, Product Manager Pharma-Security at Schreiner
MediPharm, said, “Integrating SigNature DNA in combination with
Beacon in our functional pharma labels will be setting a new
security standard in the pharmaceutical industry. DNA-Secure is
extremely robust, flexible to integrate and allows both a quick
in-field test and an ultimate forensic proof in the lab. It
provides excellent value for money and complements our portfolio of
integrated authentication features on the high-security end.”
About Schreiner Group
Schreiner Group GmbH & Co. KG is an internationally active
German family-owned business operating in the printing and
film-converting industry. The company offers tailored products,
solutions and services for the pharmaceutical and medical device
industry, logistics, mechanical engineering, the electronics and
automotive industries. In addition, Schreiner Group’s customer base
includes banks and government agencies. The product portfolio
encompasses innovative specialty labels, including self-adhesive
functional components, RFID labels, printed electronics, and
security solutions for product, brand and document protection.
Schreiner Group employs more than 1,100 people around the globe,
generating annual sales of more than 180 million euros, and is
headquartered in Oberschleissheim near Munich (Germany). Schreiner
Group’s high-tech labels are also produced in Blauvelt (New York,
USA) and in Fengpu (Shanghai, China). The company’s facilities
extend across a total area of 72,000 square meters.
For more information, visit schreiner-group.com.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and pre-clinical nucleic acid-based
therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help
protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft,
counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
Common stock listed on NASDAQ under the symbol APDN, and
warrants are listed under the symbol APDNW.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of the Private
Securities Litigation Act of 1995. Forward-looking statements
describe Applied DNA’s future plans, projections, strategies and
expectations, and are based on assumptions and involve a number of
risks and uncertainties, many of which are beyond the control of
Applied DNA. Actual results could differ materially from those
projected due to its history of net losses, limited financial
resources, limited market acceptance , the uncertainties inherent
in research and development, future clinical data and analysis,
including whether any of Applied DNA’s product candidates will
advance further in the preclinical research or clinical trial
process, including receiving clearance from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies to conduct
clinical trials and whether and when, if at all, they will receive
final approval from the U.S. FDA or equivalent foreign regulatory
agencies, ability to maintain its NASDAQ listing and various other
factors detailed from time to time in Applied DNA’s SEC reports and
filings, including our Annual Report on Form 10-K filed on December
18, 2018 and our subsequent quarterly reports on Form 10-Q filed on
February 7, 2019 and May 9, 2019, and other reports we file with
the SEC, which are available at www.sec.gov. Applied DNA undertakes
no obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date
hereof to reflect the occurrence of unanticipated events, unless
otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190807005071/en/
Investor contact: Sanjay M. Hurry, LHA Investor
Relations, 212-838-3777, shurry@lhai.com Media contact:
Meryl Rader, 781-639-4924, meryl@cgprpublicrelations.com Program
contacts: Tony Benson, +44 (0) 7552 429341,
tony.benson@adnas.com Web: www.adnas.com Twitter:
@apdn
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024